Esomeprazole in PPI Failures - IMPROVE

Study identifier:D9612L00085

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A randomised, open, phase IV, parallel group multicentre study to evaluate a change of management in Gastroesophageal Reflux Disease (GERD) patients by treatment with esomeprazole 40 mg or any other Proton Pump Inhibitor (PPI), after initial treatment failure, in ordinary clinical practice during 4 weeks.

Medical condition

Gastroesophageal Reflux Disease

Phase

Phase 4

Healthy volunteers

No

Study drug

Esomeprazole, Other PPI marketed in Sweden

Sex

All

Actual Enrollment

450

Study type

Interventional

Age

18 Years - 65 Years

Date

Study Start Date: 01 Dec 2005
Primary Completion Date: -
Study Completion Date: 01 Feb 2007

Study design

Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria